Table 1 Characteristics of patients with JIA and controls
Patients with JIA validity sample (n = 59) | Patients with JIA reliability sample (n = 37) | Controls validity sample (n = 59) | |
|---|---|---|---|
Age (yrs) | 13.6 (2.2) | 13.6 (2.1) | 13.5 (2.6) |
Female sex, n (%) | 50 (85) | 30 (81) | 50 (85) |
Height (cm) | 157.6 (12.5) | 158.5 (13.0) | 160.8 (12.3) |
Weight (kg) | 48.3 (11.8) | 49.5 (12.7) | 53.1 (15.2) |
BMI (kg/m2) | 19.2 (3.0) | 19.4 (3.3) | 20.1 (3.5) |
Waist circumference (cm) | 70.5 (9.8) | 70.2 (8.9) | 69.3 (9.2) |
Pubertal status (pre-, mid-, and postpubertal %) | 24/61/15 | 22/65/13 | 17/68/15 |
NRS current pain (0–10), n (%) score > 0 | 23 (38) | 16 (43) | 18 (30) |
NRS pain previous week (0–10) | 1.0 (0.0–3.0) | 1.0 (1.0–3.5) | 1.0 (0.0–3.0) |
NRS fatigue previous week (0–10) | 3 (2.0–6.0) | 3.0 (2.0–6.0) | 3.0 (1.0–5.0) |
Oligo/poly, n (%) | 30 (51) / 29 (49) | 18 (49) / 19 (51) | NA |
Disease duration (yrs) | 7.5 (3.8) | 7.5 (3.9) | NA |
JADAS 71 (0–101) | 3.2 (1.1–4.8) | 3.0 (1.0–4.7) | NA |
CHAQ score (0–3) | 0.0 (0.0–0.3) | 0.1 (0.0–0.4) | NA |
Off medication, n (%) | 12 (20) | 9 (24) | NA |
Synthetic DMARDs, n (%) | 39 (66) | 24 (65) | NA |
Biologic DMARDs, n (%) | 25 (42) | 15 (41) | NA |
Active disease, n (%) | 20 (34) | 12 (32) | NA |
Inactive disease, n (%) | 39 (66) | 25 (68) | NA |